February 25, 2022
Head & Senior Consultant, Division of Colorectal Surgery, Department of Surgery, National University Hospital;
Senior Consultant, Division of Surgical Oncology, National University Cancer Institute, Singapore;
Associate Professor, Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore
As both surgeon and health services researcher, Ker Kan’s primary research interests span the entire spectrum of the colorectal cancer journey – from screening and prevention, to diagnosis and treatment, and the experiences of specific subpopulations such as those with stoma or metastatic disease. His ongoing projects involve a broad range of key topics. These include understanding barriers and facilitators to colorectal screening, longitudinal quality-of-life of patients and spouses as they experience the treatment process. Apart from colorectal cancer, Ker Kan’s interests also extend to the use of telemedicine and other new models of care in health promotion and health services delivery.
Singapore Translational Cancer Consortium (STCC) has signed its first cross-border partnership with the Australian Victorian Cancer Biobank (VCB) to foster collaborations in translational oncology research. As part of the partnership agreement, STCC and VCB will share its oncology specimen databases, allowing researchers to access a wider array of tissue samples for cancer research. Both organisations will also share tissue banking best practices, and establish outreach programmes to advance clinical research collaborations between the two countries.
SINGAPORE - The development of mRNA-based cancer vaccines in Singapore is being funded by the Ministry of Health (MOH), as part of its support for “competitive cancer research projects” here, said Senior Minister of State for Health Janil Puthucheary.
SINGAPORE – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company, whose mission is to save and improve lives through early, actionable, and personalized diagnoses with its innovative RNA-powered cancer early detection solutions, announced today the signing of a Memorandum of Understanding (MOU) that launched Project CADENCE (CAncer Detected Early caN be CurEd).